Deciphera Pharmaceuticals Inc DCPH:NASDAQ

Last Price$13.46NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/29/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$12.60 (1)
Ask (Size)$15.00 (1)
Day Low / HighN/A - N/A

View Biotechnology IndustryPeer Comparison as of 06/29/2022


Deciphera Pharmaceuticals Inc ( NASDAQ )

Price: $13.46
Change: +0.11 (0.82%)
Volume: 1.00
4:00PM ET 6/29/2022

Rocket Pharmaceuticals Inc ( NASDAQ )

Price: $13.03
Change: +0.16 (1.24%)
Volume: 1.00
4:00PM ET 6/29/2022

Replimune Group Inc ( NASDAQ )

Price: $17.45
Change: +0.29 (1.69%)
Volume: 131.2 K
4:00PM ET 6/29/2022

Avid Bioservices Inc ( NASDAQ )

Price: $15.17
Change: -0.37 (2.38%)
Volume: 671.6 K
4:00PM ET 6/29/2022

Alector Inc ( NASDAQ )

Price: $10.21
Change: +0.10 (0.99%)
Volume: 301.2 K
4:00PM ET 6/29/2022

Read more news Recent News

-- Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Posts Q1 Revenue $29.2M, vs. Street Est of $27.2M
7:03AM ET 5/04/2022 MT Newswires


-- Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Posts Q1 Loss $-0.80, vs. Street Est of $-0.88
7:03AM ET 5/04/2022 MT Newswires


Deciphera Pharmaceuticals Prices $150 Million Public Offering
3:00AM ET 4/27/2022 MT Newswires

Deciphera Pharmaceuticals (DCPH) priced an underwritten public offering of 5,251,239 shares of its common stock at $10.00 per share. The company is also...

Truist Securities Adjusts Deciphera Pharmaceuticals' Price Target to $11 from $10, Keeps Hold Rating
10:28AM ET 4/13/2022 MT Newswires

Deciphera Pharmaceuticals (DCPH) has an average rating of hold and price targets ranging from $6 to $17, according to analysts polled by Capital IQ. (MT...

Company Profile

Business DescriptionDeciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA. View company web site for more details
Address200 Smith Street
Waltham, Massachusetts 02451
Number of Employees114
Recent SEC Filing06/24/20228-K
President & Chief Executive OfficerSteven L. Hoerter
Chief Financial Officer, Treasurer & Executive VPTucker Kelly
Chief Scientific Officer & Executive VPDaniel L. Flynn
Senior Vice President-Clinical DevelopmentRodrigo Ruiz Soto

Company Highlights

Price Open$13.01
Previous Close$13.46
52 Week Range$6.51 - 37.99
Market Capitalization$891.3 M
Shares Outstanding66.2 M
SectorHealth Technology
Next Earnings Announcement08/02/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$4.59
Beta vs. S&P 500N/A
Net Profit Margin-284.95%
Return on Equity-81.39%

Analyst Ratings as of 02/24/2022

Consensus RecommendationConsensus Icon
Powered by Factset